BRENTWOOD, Tenn. / Nov 10, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that the Company will participate in the 2025 Stephens Annual Investment Conference on Tuesday, Nov. 18, 2025, in Nashville, Tennessee.
Members of the management team will participate in a fireside chat on Nov. 18, 2025, at 11 a.m. ET. A live audio webcast of the event will be available in the Investor Relations section of the Ardent Health website at ir.ardenthealth.com. A replay of the event will be accessible on the same page following the session.
In conjunction with the conference, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend the conference. For more information, please contact your Stephens sales representative, or Dave Styblo, Ardent Health senior vice president of investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 employed and affiliated providers across six states. For more information, please visit ardenthealth.com.
| Last Trade: | US$9.02 |
| Daily Change: | -0.29 -3.12 |
| Daily Volume: | 854,568 |
| Market Cap: | US$1.290B |
November 12, 2025 August 05, 2025 May 06, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load